The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs and review guideline updates that support use of GLP-1 RA early in the treatment paradigm.

Learning Objectives

  • Discuss the pathophysiology of T2D and the role of different classes of glucose-lowering agents in addressing the various aspects of T2D pathophysiology.
  • Implement T2D guidelines in the selection of individualized treatment approaches.
  • Describe similarities and differences between GLP-1 RAs in terms of glycemic control, weight effects, side effects, and CV/renal benefits.
  • Apply current evidence in the individualized selection of GLP-1 RAs in those with T2D to achieve glycemic goals safely.



Javier Morales, MD, FACP, FACE

Associate Clinical Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, NY

Deborah Hinnen, APN, BC-ADM, CDCES, FAAN

Advanced Practice Nurse, Diabetes Clinic
University of Colorado Health
University of Colorado College of Nursing
Wichita State University Graduate Nursing Department
Colorado Springs, CO

Commercial Supporter

Novo Nordisk, Inc.

Education Partner

Institute for Medical and Nursing Education

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, or DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation. Pri-Med Institute and Vindico Medical Education staff have no relevant financial relationships to disclose.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.